Novo Nordisk announced the European Commission (EC) has granted marketing authorisation for Rybelsus®, (oral semaglutide), for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycemic control as an adjunct to diet and exercise.
The marketing authorisation applies to all 27 European Union member states and the United Kingdom. Rybelsus® utilises Emisphere Technologies, Inc.’s (“Emisphere” or the “Company”) (OTCBB:EMIS) proprietary Eligen® SNAC Carrier Technology.
Emisphere is a drug delivery company that utilises its proprietary Eligen® Technology to develop new oral formulations of therapeutic agents. Emisphere is currently partners with global pharmaceutical companies for the development of new orally delivered therapeutics. For more information, please visit the Company’s website at www.emisphere.com.
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company’s development activities and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the Company’s business development activities. Such statements are based on management’s current expectations, but actual results may differ materially due to various factors, including, but not limited to, the sufficiency of Emisphere’s cash position, the success of our and our partner’s development and commercialisation efforts, and our ability to successfully partner our Eligen® Technology.